Abstract
The prevention and treatment of osteoporosis is challenging in the elderly. Both early evatuation and proper management are very important to prevent an osteoporotic fracture. Recent development of the newer and stronger anti-resorptive agents is somewhat promising. However, many questions remain with regard to the treatment of osteoporosis; the selection of drugs, the duration of treatment, safety, side effects. Powerful aminobisphosphonate can cause osteonecrosis of the jaw. The increase in bone mineral density due to bisphosphonates accounts for only a quarier of their antifracture action. The evaluation of bone mineral density is not a perfect method. And, blood or urine markers of bone formation or resorption are easily affected by various factors. The follow-up interval after the initiation of drug treatment needs to be settled down. And, other supportive measures also need to be added to manage osteoporosis effectively. This communication discusses about such issues which have been appearing in recent publications.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
